Broadwater Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Broadwater Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.88M	Sell	11,900 -400	-3%	-$54.1K	1.37%	20
2026 Q1	$1.5M	Hold	12,300	–	–	1.12%	23
2025 Q4	$1.5M	Hold	12,300	–	–	1.12%	23
2025 Q3	$1.23M	Hold	12,300	–	–	0.9%	29
2025 Q2	$1.02M	Hold	12,300	–	–	0.79%	33
2025 Q1	$998K	Hold	12,300	–	–	0.78%	33
2024 Q4	$1.11M	Hold	12,300	–	–	0.85%	29
2024 Q3	$1.22M	Hold	12,300	–	–	0.9%	30
2024 Q2	$1.14M	Hold	12,300	–	–	0.88%	30
2024 Q1	$1.17M	Hold	12,300	–	–	0.9%	32
2023 Q4	$1.1M	Buy	+12,300	New	+$913K	0.86%	34

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Broadwater Capital's XBI Position: Q2 2026 in Review

Broadwater Capital reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 3.3% in Q2 2026, selling an estimated $54.1K and leaving 11,900 shares worth $1.88M. The position accounts for 1.37% of the portfolio, ranked #20.

Broadwater Capital first reported a position in XBI in Q4 2023 and has held it in 11 quarters since. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Broadwater Capital held 11,900 shares of State Street SPDR S&P Biotech ETF worth $1.88M as of Q2 2026.
Broadwater Capital sold 400 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $54.1K.
State Street SPDR S&P Biotech ETF made up 1.37% of Broadwater Capital's portfolio in Q2 2026, its #20 holding.
Broadwater Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 11 quarters since.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Broadwater Capital's 13F filing for Q2 2026, filed 24 Jul 2026.